Scott V L, Dodson S F, Kang Y
Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA.
Surg Clin North Am. 1999 Feb;79(1):23-41, vii. doi: 10.1016/s0039-6109(05)70005-0.
The hepatopulmonary syndrome is a disease entity seen in association with liver failure and other disease entities. It is a devastating consequence of liver failure that results in a significant morbidity for affected patients. Currently, there are no identified medications that ameliorate the symptoms of hypoxemia in this disease state. Recent research, however, has begun to unravel the pathobiology of the vascular dilations that arise in the lungs of patients with liver failure. In this article, a compendium of current knowledge is presented, as well as the contemporary methods for identifying and treating patients.
肝肺综合征是一种与肝衰竭及其他疾病相关的病症。它是肝衰竭的一个严重后果，会给受影响的患者带来显著的发病率。目前，尚无已确定的药物可改善这种疾病状态下的低氧血症症状。然而，最近的研究已开始揭示肝衰竭患者肺部出现的血管扩张的病理生物学机制。本文介绍了当前知识的概要以及识别和治疗患者的当代方法。
